Diabetes Medication Byetta Linked to Pancreatitis, FDA Orders Stronger Label Warning
Byetta, a Type 2 diabetes drug made by Amylin Pharmaceuticals, Inc., has been linked to six cases of hemorrhagic or necrotizing pancreatitis. Two patients have died and four others are recovering after being hospitalized, according to the U.S. Food and Drug Administration.
The recent incidents have prompted the FDA to develop stronger, more prominent warnings for the product’s label to alert consumers about the risk of acute hemorrhagic or necrotizing pancreatitis. Physicians are being cautioned to consider anti-diabetic therapies other than Byetta in patients with a history of pancreatitis.
The FDA warning comes less than a year after a link between Byetta and pancreatitis was first revealed by federal regulators. In October 2007, the FDA announced it had reviewed 30 cases of the condition in Byetta patients. At that time, the FDA asked Amylin Pharmaceuticals, Inc. to include information about acute pancreatitis in the precautions section of Byetta’s labeling.
Related posts:
- FDA Warns About Misleading Ads for Byetta, Cymbalta The Food and Drug Administration today issued warning letters to...
- Kidney Injury Risks Behind Label Change for Type 2 Diabetes Drug Byetta Labeling on the type 2 diabetes drug Byetta has been...
- Statins for Lowering Cholesterol Linked to Increased Diabetes Risks Lipitor, Crestor and other brands of statins taken by millions...
- FDA Orders Revisions to Januvia and Janumet Labeling for Acute Pancreatitis The Food and Drug Administration is warning about dozens of...
- FDA Orders Stronger Warning on Injectable Promethazine Hydrochloride (Phenergan) The sedative drug promethazine must include stronger warnings on the...
Permalink Tags: amylin pharmaceuticals, byetta, fda, hemorrhagic, necrotizing pancreatitis
